Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Phosphotyrosine Monoclonal Antibody (pY20), FITC, Invitrogen™
Mouse Monoclonal Antibody
Supplier: Thermo Scientific MA112441
Description
This antibody does not react with phosphorylated threonine or serine residues.
The role of tyrosine phosphorylation in transduction of the mitogenic signal from transmembrane receptors and in transformation by oncogene tyrosine kinases has been the subject of intense investigation for several years. While the phosphorylation of specific tyrosine residues has been shown to be a primary mechanism of signal transduction during normal mitogenesis, cell cycle progression and oncogenic transformation, its role in other areas such as differentiation and gap junction communication, is a matter of active and ongoing research. Antibodies that specifically recognize phosphorylated tyrosine residues have proved to be invaluable to the study of tyrosine -phosphorylated proteins and the biochemical pathways in which they function. The fluorescein (FITC) conjugate of clone PY20 anti-phosphotyrosine is especially useful for the detection of these P-Tyr proteins in immunohistochemical and immunocytochemical protocols in situations wherein the use of a secondary antibody would complicate detection of the protein(s) of interest.
Specifications
Phosphotyrosine | |
Monoclonal | |
1 mg/mL | |
PBS with 50% glycerol and 3mM sodium azide; pH 7.5 | |
Mouse | |
Protein A/G | |
RUO | |
Chemical | |
Antibody | |
IgG2b |
ELISA, Immunohistochemistry, Immunoprecipitation, Western Blot | |
pY20 | |
FITC | |
Phosphotyrosine; pTyr; pY | |
Phosphotyrosine coupled to carrier protien. | |
100 μg | |
Primary | |
-20° C, Avoid Freeze/Thaw Cycles, store in dark | |
Liquid | |
Chemical |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction